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ABSTRACT 
The mosquito-borne arbovirus Zika virus (positive-stranded RNA virus, ZIKV, Flavivirus, Flaviviridae), has caused an outbreak imposing by 
its extent and quick spread. This became the focus of a current pandemic and public health crisis all around the world because of the 
incessant geographic growth of both the virus and its mosquito vectors; it is often misdiagnosed with other disease like yellow fever, west 
nile, dengue and chikungunya because of same clinical manifestation. After unprecedented huge scale outbreak of ZIKV in Pacific, 
Micronesian island of Yap in 2007, though ZIKV infections are in general sporadic cases or causing mild self-limiting illness, harsh symptoms 
have been explained including neurological disorders, autoimmune disorder, fetal anomalies, impaired central nervous system of the fetus, 
microcephaly in newborns, meningoencephalitis, myelitis and Guillain Barre´Syndrome supposed to be linked with ZIKV. The virus is 
transmitted mainly by a mosquito Aedes aegypti, whereas, other routes of viral broadcast includes monkey bite, coitus and body fluids such 
as semen, blood and saliva which needs further corroboration. The relationship between these conditions with ZIKV infection is still not 
established and is under assessment. Till now there is no vaccine or specific antiviral against ZIKV, therefore the public health authority 
focuses on preventing infection, mainly in pregnant women and virus transmitted area. WHO and other health officials are working on the 
expansion of new projects and mosquito control techniques to manage up with infection as there is very fewer literature present on the 
pathogenesis of the ZIKV to help understand the clinical disease spectrum and target treatments to decrease or stop infection. The future 
status of ZIKV dispersal to other parts of the world is still unknown. The present review emphasizes various features of ZIKV and its history, 
epidemiology, transmission, clinical manifestations, progress  and advances in developing effective diagnostics, vaccines and 
drugs/therapeutics along with accepting suitable avoidance and control strategies to undertake this deadly emerging disease. 
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Among numerous public healths attentive, the global 
extend of arboviruses is of concern and alarm. Zika virus 
disease (ZVD) has lately generated important concern 
worldwide. The current outbreaks have become a major 
confront due to a change from its earlier known spectrum 
of clinical characteristics to the neurologic complications 
that are now seen1. ZIKV is a mosquito-borne virus of the 
Spondweni serocomplex, genus Flavivirus, family 
Flaviviridae. Due to the climate transforms like global 
warming, increasing population dynamics, fast 
globalization and travel, the human population is facing a 
growing emergence and outbreaks of mosquito-borne 
viruses such as chikungunya, dengue, Japanese 
encephalitis, West Nile and Zika virus2-6. Rapidly after the 
lethal outbreaks of Ebola virus in Western Africa, the most 
current emerging virus intimidating the worldwide human 
population is the ZIKV, affirmed as an emergency situation 
on Feb. 1, 2016 by the WHO for its rapid spread, affecting 
large human population in different countries with 
pandemic threats7-9. Being stayed harmless for six decades 
(first reported in 1947), the unexpected emergence of ZIKV 
with higher virulence, quick spread and inducing harsh 
clinical manifestations along with modest knowledge on 
appropriate prevention and therapeutic measures created 
massive threats for the human health10. Particularly, in 
Asia the occurrence of ZIKV infection is comparatively low 
when viral finding was done by employing RT-PCR. 
Viremia induced by ZIKV infection is comparatively low; 
thereby lessening the chance of detecting the virus in blood 
samples in acute cases. This has led the researchers to 
make the understanding of the results by taking extra 
care11, 12. In Asia and America, the strain dissimilarity could 
have been accountable for the fundamental dissimilarity in 
the epidemiology as well as the burden of ZIKV infection. 
The Asian ancestry of ZIKV is responsible for most of the 
current outbreaks in Asia as well as America13. There is a 
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obligation of using viruses generated de novo from diverse 
geographical as well as clinical sources to explain the 
pattern of ZIKV infection in Asia and America14. 
Researchers in numerous countries are trying hard to 
counter ZIKV and the Zika fever by carrying out detailed 
pathological, virological and molecular studies, rising rapid 
diagnostics, finding out potential prophylactics, drugs, 
vaccines as well as adopting suitable prevention and 
control measures15-19. Rapid diagnostics now survive for 
detecting ZIKV infection, many drug and vaccine 
candidates have also been recognized, but still any 
effective or approved treatment or vaccine is practically 
missing against this virus10. Suitable prevention and 
control strategies include limiting the spread/bite of the 
vector mosquitoes by checking their population expansion, 
safe precautions during sexual intercourse and blood 
transfusions, avoiding travel to Zika endemic countries and 
observation and monitoring are the only possible options 
to keep ZIKV infection below limits20,21. Previous reports 
on ZIKV were limited to Africa and Asia, as now it has 
global presence. ZIKV infection impacts any nation’s 
economy unfavorably besides being a toll on human 
health22. Here, we present a compilation on the Zika virus, 
covering different features of the virus and the disease it 
causes and explains the ongoing progress and advances 
being made in the field of scheming and developing 
diagnostics, drugs, vaccines along with avoidance and 
control measures to be modified to battle this viral 
pathogen of elevated public health alarms. 
HISTORY AND EPIDEMIOLOGY 
ZIKV (strain MR 766) was first remote23 from the serum 
sample of a Rhesus monkey during a research on yellow 
fever virus in the Zika forest, Uganda 1947. In 1948, the 
virus was remote from a pool of Aedes Africanus 
(Stegomya) mosquitoes in the same forest24-26. Although 
there was no sign that ZIKV caused disease in the 
occupants of Uganda, the occurrence of antibodies against 
the virus in their serum was around 10-20%. Despite the 
need for care because of antibody cross reactivity with 
other flaviviruses, a huge number of serological studies in 
the half century since the detection of ZIKV have exposed a 
broad but restricted geographic allocation of human 
infection with the virus, across a comparatively narrow 
equatorial belt running from Africa to Asia27 In 1966, the 
first non-African ZIKV strain, designated P6-740, was 
isolated from a pool of A. aegypti mosquitoes collected in 
Malaysia28. Human sickness caused by ZIKV infection was 
first reported in 1954 during an outbreak of jaundice in 
Nigeria, when infection was established in 3 patients by 
isolation of the virus or an increase in serum antibody titer, 
with a correlation observed between the development of 
ZIKV neutralizing antibodies and jaundice29. From that 
time until the early 2000s, only about a dozen cases of kind 
human ZIKV-associated illness were recognized in 
countries in Africa and Asia such as Nigeria, Uganda and 
Indonesia27. In 2007, however, ZIKV caused the first big 
outbreak outside of Africa and Asia on Yap Island, a part of 
the Federated States of Micronesia in the northwestern 
Pacific Ocean, with a comparatively mild disease 
characterized by fever, rash, arthralgia and conjunctivitis30, 
31. During this outbreak, ~73% of the 6892 Yap residents 
aged ≥3 years were estimated to be infected with ZIKV and 
~18% of the infected people had a clinical sickness that 
was most likely attributable to ZIKV infection30. Sequence 
analysis suggested that ZIKV was introduced to Yap Island 
from Southeast Asia. In the early to mid-2010s, a handful of 
intermittent cases of ZIKV infection were also reported in 
Southeast Asian countries, such as Cambodia, Thailand, 
Indonesia, Malaysia and the Philippines27. In 2013-2014, a 
major plague of ZIKV occurred in French Polynesia, a 
French overseas territory situated in the middle of the 
southern Pacific Ocean, with its ~270,000 people living on 
67 islands distributed among five archipelagoes32. During 
this outbreak, ~11% of the total population was 
predictable to have required medical treatment for 
suspected ZIKV infection33. The magnitude of the outbreak 
was most probably the result of a combination of the low 
level of preexisting immunity to ZIKV and the high density 
of capable mosquito vectors in that area34. Although a huge 
majority of the clinical cases seen in this outbreak were 
alike to those pragmatic in the 2007 Yap outbreak, a little 
fraction of harsh cases were linked with neurological 
complications, such as Guillain-Barré syndrome, in the 
context of co-circulating dengue and chikungunya33,35. 
Retrospectively, the incidence of Guillain-Barré syndrome 
was predictable to be increased by ~20-fold in French 
Polynesia35. Although the origin of the ZIKV in French 
Polynesia remains unknown, it is genetically related to the 
strains isolated from Yap Island in 2007 and from 
Cambodia in 201032. During or shortly after the French 
Polynesia outbreak, ZIKV extend further to other adjacent 
islands in the South Pacific Ocean, including the Cook 
Islands, New Caledonia and Easter Island. Also, it was 
imported to other distant countries such as Italy, Australia, 
Japan and Norway27. At the start of 2015, the first 
autochthonous broadcast of ZIKV was detected in the 
northeastern part of Brazil, in relationship with an 
outbreak of an acute exanthematous sickness36. Toward 
the end of 2015, ZIKV activity prolonged into at least 14 
Brazilian states37, with an estimated 440,000-1,300,000 
suspected cases. To our shock, it was noted in Brazil that 
the number of newborn infants with microcephaly had 
increased in the ZIKV-affected areas by Sep. 201538 and 
N4000 cases of supposed microcephaly were reported by 
Feb. 2016, although these cases may have been 
misdiagnosed in some cases or over-reported39. In 
agreement with this finding, retrospective studies in 
French Polynesia indicated an increased number of 
examples of microcephaly and other fetal abnormalities 
after the 2013-2014 ZIKV outbreaks. In Oct. 2015, 
Colombia reported the local transmission of ZIKV infection 
outside Brazil and by March 2016, a total of 51,473 
suspected ZIKV infections were recorded in that country, 
with 2090 laboratory-confirmed cases. Since its 
appearance in Brazil, ZIKV has spread at an alarming rate 
throughout much of Central and South America and the 
Caribbean and the possibility that microcephaly is linked 
to ZIKV has increased, prompting the WHO to speak out a 
public health emergency of international concern from Feb. 
to Nov. 2016 40,41. ZIKV is still causing an unprecedented 
ongoing plague in Latin America and threatening North 
America and potentially the rest of the world. As of Nov. 
17, 2016, 48 countries and territories in the Americas had 
reported the autochthonous mosquito-borne transmission 
of ZIKV, with an accumulated number of 171,553 
confirmed cases. Sexually transmitted cases have also been 
reported in Chile, Argentina, Canada, Peru and the US. In 
Nov. 2016, a decreasing tendency in ZIKV cases had been 
noted in all the ZIKV-affected countries and territories in 
the Americas, except for Mexico, Panama and the islands of 
Turks and Caicos42. To date, a total of 20 countries and 
territories in the Americas have documented 2311 
confirmed cases of ZIKV-associated congenital syndrome42, 
43. In the US states and federal districts, there were 4444 
confirmed ZIKV cases reported to ArboNET as of Nov. 23, 
2016; of these, 36 were sexually transmitted cases 
throughout the country and 182 were locally acquired 
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mosquito borne cases in Florida, where autochthonous 
transmission was first reported in July 2016 and is 
currently ongoing in the area of Miami Beach and in the 
county of Miami Dade. By Nov. 17, 2016, a total of 33 
newborn infants and pregnancy losses with birth defects 
had been reported to the US Zika Pregnancy Registry44. 
VIROLOGY 
The ZIKV belongs to the family Flaviviridae and the kind 
Flavivirus. Flaviviruses belong to a group of viruses labeled 
as arborviruses, which is an expressive term that refers to 
hundreds of RNA viruses which rely on arthropods such as 
mosquitoes or ticks for broadcast. Arboviruses cause some 
of the most overwhelming diseases in humans and animals 
universal. There are a total of 7 groups of mosquito-borne 
flaviviruses, according to the International Committee on 
Taxonomy of Viruses. The groups are categorized based on 
antigenic and genetic deliberations. The genus Flavivirus 
consists of 39 diverse mosquito-borne viruses45. The ZIKV 
(Fig.1) is composed of a positive sense, single strand RNA 
genome. It is an enveloped, icosahedral virus that is an 
associate of the Spondweni clade. The ZIKV is a positive 
polarity RNA virus with a genomic size of about 12 kb that 
is uncoated immediately after virus entry into the host 
cells46. The single open reading frame sequence of its RNA 
genome encodes a polyprotein which comprises the 
structural architecture of the virus47. This polyprotein 
contains 3 components, including a capsid (105 aa), 
membrane and premembrane piece (187 aa) termed C, M 
and P, respectively. There is also an envelope protein (E, 
505 aa) and an adding 7 components that are non-
structural (NS). These 7 proteins are selected NS1 (352 aa), 
NS2a (217 aa), ND2b (139 aa), NS3 (619 aa), NS4a (127 
aa), NS4b (255 aa) and NS5 904 aa) 48. The NS protein 
NS2B/NS3 includes a serine protease that along with host 
proteases cotranslationally and post translation cleaves 
the polyprotein into its components. The envelope protein 
is the primary flavivirus antigenic site and says attachment 
of the virion and penetration into the host cell. Folding of 
the E protein is controlled by the premembrane protein, 
which is cleaved by furin to form the membrane protein 
prior to mature virion release from the cell49. The purpose 
of the remaining NS proteins remains unknown, but may 
have precise essential roles in various replication stages. 
For example, NS5, the most highly preserved of the 
flavivirus NS proteins functions as a RNA-dependent RNA 
polymerase50. Phylogenetic study of the ZIKV genome 
indicates the survival of three lineages: West Africa, 
Asian/American51,52 and Brazilian ZIKV53. Further analyses 
of Asiatic and African ZIKV strains isolated from infected 
mosquitoes, monkeys and humans showed important 
amino acid variations throughout the sequence of the viral 
polyprotein54. The same study associated the human 
strains isolated during the recent outbreaks with the viral 
strain P6-740 (from Asian mosquito, 1966) and 
established that all strains have a common ancestor. 
However, all the recent strains present a minimum of 400 
amino acid mutations when compared with P6-740, which 




Figure 1: Structure and genome of Zika virus 81 
TRANSMISSION OF THE ZIKA VIRUS 
ZIKV is transmitted to humans mostly through the bite of 
infected daytime active mosquitoes. The two main 
transmission cycles are (Fig. 2): (i) a sylvatic cycle between 
non-human primates and arboreal canopy-dwelling 
mosquitoes (Ae. africanus, Ae. bromeliae, Ae. dalzieli, Ae. 
furcifer, Ae. luteocaphalus, Ae. opok, Ae. taylori, Ae. 
unilineatus, Ae. vittatus) and (ii) an urban cycle with 
humans as both reservoir and intensification hosts, and 
anthropophilic mosquitoes as vectors (primarily, Aedes 
aegypti and secondarily, Aedes albopictus). The insinuation 
of Ae. aegypti as the main vector is supported by frequent 
isolation of ZIKV from field-collected mosquitoes55-59 and 
experimental proof of ability to transmit ZIKV60. Ae. 
albopictus has been suggested to be involved in 
transmission as ZIKV has been detected in pools of 
mosquitoes collected in Gabon and Brazil61,62 and 
transmission demonstrated in laboratory. ZIKV, as most 
arboviruses, has the potential to persevere in mosquito 
eggs. The virus can be acquired by the offspring by vertical 
transmission from infected mothers through (i) 
transovarial transmission when the virus infects germinal 
tissues in the ovaries and (ii) trans-egg transmission when 
infection occurs during fertilization63. VT has been 
demonstrated in Ae. aegypti and Ae. albopictus mosquitoes. 
This option has already been suggested by the detection of 
ZIKV from field-collected Ae. furcifer males in southeastern 
Senegal55. VT is another mechanism by which a virus can 
extend in a mosquito population. Males cannot get the 
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virus from a blood meal but can acquire virus by VT from 
an infected female parent. In trial studies, it has been 
shown that infected male Ae. aegypti can transmit the virus 
horizontally to non infected adult females during mating. 
Thus VT in Aedes mosquitoes may have a role in the 
preservation of ZIKV in nature. In addition to vector-borne 
transmission, direct human-to human transmission of ZIKV 
has been documented: in utero from infected mothers to 
fetus, sexually through secretions predominantly from 
male to female, blood transfusion, saliva, urine, through 
breast feeding60. The significance of these non-vector-
borne ZIKV transmission routes is difficult to measure. 
However, these numerous modes of transmission are 
improbable to be as significant as mosquito-borne 
transmission, as suggested by their insignificant effect 
during seasons not permissive for mosquito activity. Beside 
kind symptoms, ZIKV can cause neurological disorders 
such as Guillain-Barre syndrome in adults64,65 and 
microcephaly in newborns66. Zika has been then affirmed 
an emerging global health threat by the WHO. 
  
 
Figure 2: Transmission of Zika virus60 
 
CLINICAL MANIFESTATION OF ZIKA VIRUS 
DISEASE 
About 80% of ZIKV infections are asymptomatic67. 
Symptomatic infections are characterized by a self-limiting 
febrile illness which typically lasts 4-7 days and is 
connected with maculopapular rash, arthralgia, especially 
affecting the small joints of the hands and feet, 
conjunctivitis, back pain and mild headaches. Within 2 
days, the skin rash begins to lighten spontaneously and 
within 3 days, fever starts to resolve and only few rash 
persists68. Other less common clinical features include 
nausea, diarrhoea, abdominal pain, ulcerations of mucous 
membranes, uveitis and palatal petechiae68,69. Harsh ZVD 
may be seen following in utero infection leading to 
neurological complications, notably microcephaly and 
Gullian-Barre syndrome. Meta-analysis showed that 
occurrence of ZIKV associated GBS and microcephaly (Fig. 
3) among all pregnancies were 1.23% and 2.3% 
respectively70,71. Other neurological manifestation seen 
include spasticity, seizures, craniofacial disproportion, 
irritability and brainstem dysfunction, feeding difficulties 
and ocular abnormalities72. Neonates with ZVD usually 
have intrauterine growth restriction; other features may 
include a transient diffuse rash, conjunctivitis and 
conjunctival injection. Ocular abnormalities such as focal 
pigment mottling, chorioretinal macular atrophy, optic 
nerve abnormalities, cataract, intra-ocular calcifications, 
microphthalmia, conjunctival injections, optic disc cupping, 
lens subluxation in addition to bilateral iris coloboma, 
foveal reflex loss, macular hypoplasia and scarring73. 
Several foetal neuronal abnormalities have been 
demonstrated when ultrasound was done at 29 weeks 
gestation; this include brain atrophy, large cysterna magna, 
severe unilateral ventricular enlargement, corpus callosum 
and vermian dysgenesis, absence or redumentary 
thalamus, thin brainstem and pons calcifications involving 
frontal lobes white matter, caudate, lenticulostriatal 
vesssels and cerebellum68. Neuroimaging (computed 
tomography and magnetic reasoning imaging) 
characteristics commonly reported in newborns include 
enlarged cisterna magna, hypogenesis of corpus callosum, 
ventriculomegaly, delayed myelination, cerebellar and 
brainstem hypoplasia, calcifications in the junction 
between cortical and subcortical white matter and cortical 
malformations like polymicrogyria in the frontal lobes. 
Interestingly, abnormality of frontal lobe has not been 
reported in other congenital infections68. Congenital Zika 
syndrome refers to the range of abnormalities seen in 
neonates following Zika infection in pregnancy74. This 
includes visual, hearing and other neurological 
abnormalities (including neuroimaging findings) 75. 
Complete cranial growth may be attained at 30 weeks76. 
Therefore, ZIKV infection in late pregnancy may not affect 
head size. The sensitivity of microcephaly in detecting 
probable or definite ZIKV infection is 83%. It has thus been 
suggested that microcephaly should not be a necessary 
criterion for diagnosis of CZS74. The Centres for Disease 
Control and prevention, the USA has described five features 
to define CZS which include: severe microcephaly with 
partially collapsed skull; specific pattern of brain damage 
including subcortical calcifications and decreased brain 
tissue; damage to the back of the eye, including macular 
scarring and focal pigmentary mottling of the retina; 
congenital contractures such as club foot or arthrogryposis 
and hypotonia which restricts foetal body movement soon 
after birth77. Regularly characterising this syndrome may 
be a challenge in resource constraint settings, with scarcity 
Khatri et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2018; 8(6-s):320-327   
ISSN: 2250-1177                                                                                 [324]                                                                                  CODEN (USA): JDDTAO 
of high cadre health workforce. Therefore, it is needful to 
develop a simple algorithm that low cadre health worker 
can readily identify. This is further compounded by 
challenge of confirming maternal Zika infection.  
 
Figure 3: Congenital birth defects (Microcephaly) 
source: https://indianexpress.com 
DIAGNOSIS 
Although the diagnosis is difficult as the symptoms are 
gentle and not so accountable, some tests at molecular level 
are in present use.  Diagnosis for ZIKV infection includes 
PCR tests to notice viral DNA as well as additional tests to 
detect ZIKV antibody (IgM) in serum78,79. IgM for ZIKV is 
typically detectable around 35 days following infection, but 
cross reactivity with closely related dengue, yellow fever, 
japanese encephalitis and west nile viruses are possible. 
These cross hasty results were more common in patients 
that denoted signs of previous flavi virus infection than 
patients with primary ZIKV infection. PCR tests should be 
conducted within 10 days of onset of illness. For best 
diagnosis practices, serum samples should be analyzed as 
early as possible with a second test 2 to 3 weeks after 
that80. Several methods can be used for diagnosis, such as 
viral nucleic acid detection, virus isolation and serological 
testing. Nucleic acid detection by RT-PCR targeting the 
nonstructural protein 5 genomic region is the primary 
means of diagnosis, while virus isolation is largely for 
research purposes. Saliva or urine samples collected during 
the first 3 to 5 days after symptom onset or serum collected 
in the first 1 to 3 days, are suitable for detection of ZIKV by 
these methods. It has been experiential that ZIKV can be 
detected for rapidly in saliva sample than in serum sample. 
Serological tests, including immune fluorescence assays 
and enzyme linked immune sorbent assays may indicate 
the presence of anti ZIKV IgM and IgG antibodies. Care 
should be taken with serological results as IgM cross 
reactivity with other flavi viruses has been reported in both 
primary infected patients and those with a probable 
history of prior flavivirus infection81. ZIKV can be detected 
from urine, serum and maternal milk during post partum 
period of new mother to identify whether the newborn 
baby she delivered has microcephaly or not82. It is also 
significant report about all the symptoms of present 
situation as well as the health issues of recent past to the 
medial stuffs to detect the coin fections which will further 
help in better diagnosis and treatment82-84. 
TREATMENT AND PREVENTION 
At the instant, no preventive medicines or vaccines are 
available. Since zika presents asymptomatically or with 
mild symptoms, symptoms may be controlled with bed 
rest, intravenous fluids and acetaminophen85. The major 
challenge of zika is the difficulty of infection; effort should 
be placed on antiviral agents, vaccines and other 
preventive measures. About 30 FDA approved antiviral 
agents have been evaluated and were found to have 
important anti-Zika viral activity86. However, the antiviral 
effects were mainly determined using the Asian strains. It 
is therefore significant to determine this antiviral activity 
against African strains. The common preventive measures 
include preventing mosquito bites and sexual transmission. 
Measures of preventing mosquito bites include: wearing 
long sleeve shirts and long dresses, permethrin 
impregnated clothes, indoor residual spraying of 
insecticide, screening of doors and windows against 
mosquitoes and other environmental control measures 
meant at reducing or eliminating the breeding of 
mosquitoes85. Prevention of sexual transmission is 
particularly important when the sexual partner is 
pregnant. Sexual transmission can be prevented through 
abstinence or by using condom. Due to blood transfusion 
related transmission, it is needful to provide reasonable 
cost effective safe blood transfusion services in resource 
unnatural settings. This would include pre donation 
screening to rule out possible Zika infection and cost 
effective Zika serological test with high sensitivity. This is 
particularly important in pregnant women requiring blood 
transfusion. There are several candidate vaccines at 
various developmental stages, some are live attenuated, 
inactivated and others are genetically engineered vaccine 
constructs. Among these vaccines, there is one that targets 
both dengue and ZIKV87. It will be more helpful to develop 
multi flavivirus vaccine that can be used in resource limited 
settings with high and multiple flavivirus infections. 
All conventional system of medicine specifically 
homeopathy and ayurveda, may be attempted in ZIKV case, 
the cause is that homeopathic preparation has already 
shown effective in case of Japanese encephalitis virus 
which falls in the same genus like ZIKV. 
POTENTIAL HOMEOPATHIC MEDICINES FOR ZIKV 
Homeopathic prescriptions Eupatorium perfoliatum, Atropa 
belladonna, Rhus tox may be firmly utilized as a part of 
ZIKV treatment. These medications come the nearest in 
treating the symptoms of ZIKV infection disease. 
Homeopathy has been very effective in treating epidemic 
diseases such as cholera, dengue fever, yellow fever, typhus 
and conjunctivitis. In an outbreak when an immense 
number of individuals are beaten by acute and similar 
sufferings from similar cause, homeopathy may be an 
excellent prophylactic help. Records show that during 
epidemics, homeopathic pharmaceuticals are of huge help 
in diminishing the death when contrasted with those put 
under conventional system of medicines. Atropa 
belladonna is a medicinal plant categorized under 
Solanaceae family. This plant has huge commercial 
importance as it is a major source of pharmaceutical 
bioactive compounds like alkaloids mainly scopolamine 
and hyoscyamine and is native to Western Asia Europe and 
North Africa. Although, all alkaloids in Atropa belladonna 
are dispersed in the entire plant, but the majority of the 
alkaloid content is found in green leaves and ripe fruit. It 
has long been used in human medicine for the treatment of 
inflammation, headache, peptic ulcer, menstrual symptoms 
and histaminic reaction88,89. In our studies Belladonna 
treatment productively abridged the Japanese encephalitis 
virus infection90. This may be attempted in case of ZIKV 
after proper consultation with the physician, since they 
both belong to same family. In homeopathy, ultra-diluted 
concentration like 3, 6, 30, and 200 of above mention drugs 
are prescribed for the treatment of all infectious diseases. 
Therefore, homeopathy may have a enormous role to play 
as prophylactic when disease spreads suddenly over a 
substantial region. Additionally, homeopathic 
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pharmaceutical Eupatorium perfoliatum may be utilized as 
prophylactic as a part of ZIKV, as this drug has the nearest 
match to the symptoms displayed in ZIKV disease. 
POTENTIAL AYURVEDA MEDICINES FOR ZIKV 
Ayurveda is an ancient medical science which is based on 
naturally occurring herbal medicine and showed some 
efficient preventive and healing answers for most of the 
sicknesses. The most significant aspect of the ayurvedic 
system of medicine is that, they are completely based on 
naturally happening substances and therefore, totally 
secure for human consumption without showing any side 
effect. It has been asserted that Tinospora cordifolia is one 
of the effective natural solutions for the counteractive 
action of any sort of viral disease. It is considered as a 
potential immunomodulator. It is thought that, it reinforces 
the safe framework and assembles resistance in the body 
to battle infections. Tinospora Cordifolia is likewise an 
effective solution for treating fevers chiefly from unknown 
reasons. This herb, which has been utilized as a part of 
ayurveda, since hundreds of years, is extremely useful in 
boosting up immune function and the body’s capacity to 
fight against infections. Ayurvedic herbs helps in enhancing 
the phagocytic capability of the immune cells especially 
macrophages. The astringent properties present in the 
medication show against infrequent and antispasmodic 
properties which are again useful in forestalling infectious 
sicknesses like intestinal sickness, dengue and swine 
influenza91. Tinospora cordifolia has also shown its 
effectiveness in case of other diseases like dengue fever, 
swine influenza and urinary tract infections hence may be 
an efficient remedy for ZIKV infection too. 
FUTURE PROSPECTIVE AND CONCLUSIONS 
As the number of cases of ZIKV infection is increasing 
radically, some necessary steps should be taken to 
eradicate this deadly infection and to inhibit the entry of it 
in future as well. ZIKV has acquired a prominent place 
among several dreaded infectious diseases which are of 
great concern among the people around the globe. Its 
major concern is in pregnant women wherein it causes 
microcephaly, visual impairment and autoimmune 
disorders namely Guillain Barre´Syndrome. The virus 
mainly spreads through the bite of mosquito (Aedes spp.), 
hence prevention and control of mosquitoes become of 
prime importance to keep transmission of Zika under 
check. Randomized control trials (RCT) must be carried out 
for preventing an epidemic. In addition to checking vector 
transmission, it is also necessary to prevent non-vector 
transmission of ZIKV as it also has some role to play in 
maintaining its cycle. For this purpose, public awareness 
about the disease epidemiology and transmission is 
necessary. Diagnosis of ZIKV can be achieved by the 
isolation and identification which requires biosafety 
procedures, serological assays like ELISA which can show 
cross-reaction with other flaviviruses, nucleic acid 
detection methods like RT-PCR, real-time RT-PCR, 
RTLAMP, etc. Samples like urine, amniotic fluid and other 
body fluids can be used for diagnosis of ZIKV. Advanced 
diagnostic techniques like LAMP, lateral flow assay, 
microarray, nanotechnology can be used for accurate and 
effective diagnosis of Zika. Accurate phenotyping and serial 
electrophysiology can provide insight into GBS 
pathogenesis, especially on the occasions during lack of 
pathological samples. Presently, several companies are on 
the verge of designing an effective vaccine against ZIKV. 
Point-of-care diagnostic kit is the need of the hour to give 
an early diagnosis for implementing patient care with 
immediate effect. Efforts must be made for discovering 
effective drugs to counter ZIKV infection. Several herbal 
drugs have also been studied to find out an effective 
control strategy. Further insights into the viral 
pathogenesis and molecular studies can aid in sketching a 
better vaccine and treatment options to control ZIKV 
disease. The research gaps such as the frequency and 
spectrum of outcomes in the case of ZIKV infection of the 
fetus must be understood fully; vis-à-vis, there is also need 
to understand the environmental factors that influence 
outbreaks. All these will ultimately help to design new 
products for control of vectors; therapeutics with high 
efficacy; and effective vaccines for protection of humans. 
We need to proceed with a sense of urgency in this context. 
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